marketing-medtech

**Founder:** Gregory Steven Hanson — Directeur General, DECIPHR HEALTH (SAS); Co-Founder, Deciphr Health Inc. (US parent)
**Background:** clinician | verified: True — Gregory Hanson, MD, MPH is a physician (clinician) and Co-Founder of Deciphr Health. He earned his MD from Sidney Kimmel Medical College at Thomas Jefferson University (medical school previously associated with Geisel/Dartmouth in his earlier training narrative), an MPH in Epidemiology and Applied Biostatistics from Columbia University Mailman School of Public Health, and a BS from UCLA. He completed a Diagnostic Radiology residency (2018-2024) at Thomas Jefferson University Hospitals and specializes in Interventional Radiology. He is a member of the Society of Interventional Radiology, RSNA, and the American Roentgen Ray Society. Prior roles include GoodRx/flipMD, Thomas Jefferson University Hospitals, and Columbia University Medical Center. The "clinician" claim is supported: he is a credentialed, residency-trained physician.</actual_background>
<parameter name="evidence">Doximity (a verified physician directory) lists "Dr. Gregory Hanson, MD" with title "Physician," specialty "Interventional Radiology," medical degree from Sidney Kimmel Medical College at Thomas Jefferson University, and a "Residency, Radiology-Diagnostic, 2018-2024." His LinkedIn handle is "gregory-hanson-md-mph" (MD, MPH credentials), listing him as Co-Founder of Deciphr Health with prior clinical roles at Thomas Jefferson University Hospitals and Columbia University Medical Center. The Dartmouth Geisel School of Medicine article ("Road to Geisel - Greg Hanson," 2014) documents him as a medical student, noting he was "inspired to pursue a career in medicine" after shadowing emergency medicine physicians. These three independent sources (a verified physician directory, an MD-credentialed LinkedIn profile, and an official medical-school publication) corroborate that he is a trained, practicing clinician/physician.
**Stage / fundraise:** Very early. French SAS incorporated 2026-03-09 (SIREN 102174638, SIRET 10217463800019), HQ 60 rue Francois Ier, 75008 Paris, NAF 32.50A (medical/dental instruments). It is a subsidiary: the SAS President is the legal entity DECIPHR HEALTH INC. (US parent, filed in NY/CA around Dec 2025). No employee headcount declared yet (tranche_effectif NN). / Unconfirmed. No public funding announcement found (no Crunchbase/Tracxn round, no press). Given the SAS President is the US parent DECIPHR HEALTH INC., the French entity's capital source is most likely intercompany funding from the US parent rather than a standalone French raise. Verify autonomy/budget control before outreach.
**Regulatory trigger:** High. Product is a wearable biosensor system with AI-powered alerts for high-risk pregnancy (maternal/fetal parameter monitoring 24/7, "algorithms identify patterns and predict potential risks"). An AI/algorithm-driven monitoring device that flags clinical complications is a medical device (likely Class IIa/IIb under EU MDR) and the AI/software component falls under IEC 62304 / MDR technical documentation. Selling into the EU via the French SAS requires CE/MDR conformity — a clear compliance-evidence milestone ahead.
**Email:** (confidence none) — No published email address was found. The deciphr.health site references a "Contact"/"Get in Touch" section but exposes no address, and the /contact path returns 404. No verified email pattern (e.g. firstname@) could be confirmed from a published source, so no guess is provided. Best reachout channel is the founder's LinkedIn.
**LinkedIn:** https://www.linkedin.com/in/gregory-hanson-md-mph-95671a5a/ (founder); https://www.linkedin.com/company/deciphr-health (company) **Website:**
**Score:** 10 -> Tier B
**Hook:** A new Paris SAS building an AI wearable for high-risk pregnancy faces a real EU MDR / IEC 62304 wall before it can sell in France/EU — and a clinician founder shouldn't have to assemble a regulated-software team to clear it. OmDev plugs in senior devs + AI + a dedicated CTO at a fixed monthly price (~3x cheaper than hiring the team in-house), the client owns the code, and the pipeline produces the compliance evidence MDR auditors expect: SOUP register signed every build and full requirements-to-code-to-test traceability feeding the IEC 62304/MDR file (OmDev does not certify). Note: confirm the French entity controls its own engineering roadmap vs. the US parent before pitching.

---

## Founder & background
Gregory Steven Hanson (b. 1988) is the **Directeur General** of the French SAS and **Co-Founder** of US parent Deciphr Health Inc. He is a **physician**: MD from Geisel School of Medicine at Dartmouth (2014-2018) plus an MPH, with clinical roles at Thomas Jefferson University Hospitals and Columbia University Medical Center, and commercial healthcare experience at GoodRx / flipMD; he is based in Paris ([RocketReach](https://rocketreach.co/gregory-hanson-email_97009932); [LinkedIn](https://www.linkedin.com/in/gregory-hanson-md-mph-95671a5a/)).
Background = clinician (with GoodRx commercial exposure), which ranks below finance/insurance and serial/pharma in OmDev's ICP, so this is a moderate-priority founder profile.

## Funding & momentum
The French entity is brand new — **incorporated 2026-03-09**, SIREN 102174638, HQ 60 rue Francois Ier, 75008 Paris, NAF 32.50A ([Annuaire API](https://recherche-entreprises.api.gouv.fr/search?q=deciphr)). Its **President is the US parent DECIPHR HEALTH INC.** (filed in NY/CA ~Dec 2025: [Bizapedia](https://www.bizapedia.com/ca/deciphr-health-inc.html)).
No public funding round was found; the French SAS is most plausibly funded intercompany by the US parent, so a standalone French raise is unconfirmed — verify capital/autonomy before outreach.

## Product & regulatory
Deciphr Health sells **always-on wearable biosensors for high-risk pregnancy** — 24/7 maternal/fetal monitoring, app integration, and **AI-powered alerts that "predict potential risks before they become critical"** ([deciphr.health](https://deciphr.health/)).
An AI-driven device that flags clinical complications is a medical device (likely **Class IIa/IIb under EU MDR**) with a software component under **IEC 62304**; selling in France/EU requires CE/MDR conformity — a concrete compliance milestone ahead.

## Pain & buying signals
3-month-old SAS with **no declared headcount**, no visible local CTO, a Lovable-built marketing site, and a 404 contact page — all point to a lean early local setup facing a heavy MDR/62304 evidence burden.
**Counter-signal:** the US parent likely owns core engineering and IP, which may limit the French entity's authority to commission a dev partner.

**Why OmDev fits:** OmDev gives this clinician founder a senior dev team + AI + a **dedicated CTO at a fixed monthly price (~3x cheaper than in-house)**, with the client owning the code and a pipeline that emits the MDR-grade compliance evidence (signed SOUP register per build + requirements→code→test traceability feeding the IEC 62304/MDR file; OmDev does not certify) — exactly the gap between a new SAS and EU market entry. Qualify first whether engineering decisions sit in Paris or with the US parent.

*Email: none published; reach via [founder LinkedIn](https://www.linkedin.com/in/gregory-hanson-md-mph-95671a5a/).*

---
**Sources:** https://recherche-entreprises.api.gouv.fr/search?q=deciphr (SIREN 102174638) · https://deciphr.health/ · https://rocketreach.co/gregory-hanson-email_97009932 · https://www.linkedin.com/in/gregory-hanson-md-mph-95671a5a/ · https://www.linkedin.com/company/deciphr-health · https://www.bizapedia.com/ca/deciphr-health-inc.html · https://www.bizprofile.net/ny/chester/deciphr-health-inc